期刊文献+

一种新型的乙型肝炎病毒剪接变异体 被引量:3

A novel spliced variant of hepatitis B virus genome generated by pregenomic RNA splicing
原文传递
导出
摘要 目的 证实乙型肝炎病毒 (hepatitisBvirus,HBV)前基因组RNA在 4 5 8nt~ 130 8nt(nt,核苷酸 )之间可发生剪接并产生相应的基因组剪接变异体。方法 对 1株分离自慢性乙型肝炎患者血清的亚基因组HBVDNA(2 36 6bp)进行测序并以VectorNTI6 .0软件进行分析。将全基因组HBVDNA(32 15bp)理论上可能的剪接供体及受体内的核苷酸进行定点突变并将突变株转染HepG2细胞 ,以位于HBVDNA 4 5 8nt及 130 8nt两侧的特异引物检测转染后的细胞内HBV核心颗粒DNA ,并以相同引物检测 4 5 8nt~ 130 8nt发生缺失的HBVDNA在不同病程的乙型肝炎患者血清中的存在情况。结果2 36 6bpHBVDNA在 4 5 8nt~ 130 8nt之间发生缺失并符合GT AG剪接模式。 32 15bp全基因组HBVDNA在 4 5 9nt及 130 6nt分别发生G→A及A→C突变后均不能产生 4 5 8nt~ 130 8nt缺失。 4 5 8nt~130 8nt发生缺失的HBVDNA在慢性乙型肝炎、肝硬化及原发性肝细胞癌患者血清的检出率分别为80 %、75 %及 70 % ,显著高于HBV无症状携带者 10 %的检出率。结论 HBV前基因组RNA在 4 5 8nt~130 8nt之间可发生剪接并产生长度为 2 36 6bp的基因组剪接变异体。该类型基因组剪接变异体基因结构特点及在HBV相关性肝病中广泛存在提示它与HBV致病性密切相关。 Objective To verify that spliced variant of hepatitis B virus genome can be generated by pregenomic RNA splicing ranging from 458nt to 1?308nt. Methods A subgenomic HBV DNA with 2?366bp isolated from a patient with chronic hepatitis B was sequenced and analyzed by Vector NTI6.0 software. Nucleotide within the theoretical splicing donor and acceptor in full length HBV genome mutated respectively and the mutants were used to transfect the HepG2 cells. Intracellular core particles were harvested and a pair of primer flanking the 458nt-1?308nt region was used to amplify the HBV DNA within the core particles. The same primers were also used to detect the presence of HBV DNA with the deletion in the region of 458nt-1?308nt in the serum from the patients with different clinical manifestations. Results 2?366bp HBV DNA showed deletion in the region spanning from 458nt to 1?308nt as compared to the full length counterpart and this type of deletion fitted with the GT-AG splicing mode. Either the point mutation from G to A in 459nt within the putative splicing donor or from A to C in 1?306nt within the putative splicing acceptor in 3?215bp full length HBV DNA vanished the 458nt-1?308nt deletion in HBV genome. 458nt-1?308nt deletion could be detected in the patients with chronic hepatitis, cirrhosis or hepatocellular carcinoma with the rate of 80%, 75% and 70% respectively, and they were much higher than 10% in asymptomatic carrier. Conclusions Spliced variant of hepatitis B virus genome with the length of 2?366bp was generated by HBV pregenomic RNA splicing ranging from 458nt to 1?308nt. Characteristics of gene organization and prevalence in HBV-related diseases indicated that such type of spliced variant may be closely related to pathogenesis of HBV.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2003年第11期844-848,共5页 Chinese Journal of Microbiology and Immunology
基金 福建省重大科技基金资助项目 (2 0 0 2F0 0 5 )
关键词 乙型肝炎病毒 剪接变异体 聚合酶链反应 转染 Hepatitis B virus RNA splicing Polymerase chain reaction Transfection
  • 相关文献

同被引文献40

  • 1向光明,钟森.乙肝病毒基因组变异与肝细胞癌的关系研究进展[J].国外医学(病毒学分册),2005,12(3):65-67. 被引量:7
  • 2陈婉南,黄清玲,林建银,王林,郭丹华,林旭.双剪接型2.2 kb乙型肝炎病毒基因组剪接变异体编码蛋白的反式激活作用[J].中华微生物学和免疫学杂志,2006,26(11):985-989. 被引量:4
  • 3王林,柏世玉,陈婉南,李晖,林建银,林旭.乙型肝炎病毒DNA聚合酶末端蛋白抗α-干扰素功能区域分析[J].中华微生物学和免疫学杂志,2007,27(6):540-545. 被引量:5
  • 4Wu HL, Chen PJ, Tu SJ, et al. Characterization and genetic analysis of alternatively spliced transcripts of hepatitis B virus in infected human liver tissues and transfected HepG2 cells. J Virol, 1991, 65(4) : 1680-1686.
  • 5Soussan P, Garreau F, Zylberberg H, et al. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest, 2000, 105(1) : 55-60.
  • 6Rosmorduc O, Petit MA, Pol S, et al. In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA. Hepatology, 1995, 22(1) : 10-19.
  • 7Foster GR, Ackrill AM, Goldin RD, et al. Expression of the term inal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natt Acad Sci USA, 1991, 88(7) : 2888-2892.
  • 8Craxi A, Di Bona D, Camma C. Interferon alpha for HBeAg posi- tive chronic hepatitis B. J Hepatol, 2003, 39 (Suppl 1 ): 99- 105.
  • 9Brooke MG, McDonald JA, Karayiannis P, et al. Randomised controlled trial of interferon α 2a (RoferonA) for the treatment of chronic hepatitis B virus infection: factors that influence response. Gut, 1989, 30(8) : 1116-1122.
  • 10Foster GR, Goldin RD, Hay A, et al. Expression of the terminal protein of hepatitis B virus is associated with failure to respond to interferon therapy. Hepatology, 1993, 17 (5) : 757-762.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部